As of Nov 19, 2026, 1 of 1 active firms rate BNGO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BNGO EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 1 analysts
Next period, 1 analysts expect Bionano Genomics Inc to earn — a share (range — – —), versus — a year earlier. Full-year consensus is $-2.14, growing to $-0.97 the year after.
REVENUE · NEXT QUARTER
$8.4M
Range $8.4M – $8.4M · 1 analysts · +26% YoY
Revenue is expected to reach $8.4M (range $8.4M – $8.4M), +25.6% year-over-year. Full-year consensus is $32.5M, rising to $43.3M next year.
Top analysts covering Bionano Genomics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BNGO.
#1
SJ
Sung Ji Nam
Scotiabank · Rank #186
Neutral
$4.00+309.8% to target
Overall win rate
47%
+ Follow
#2
Mark Massaro
BTIG · Rank #220
Neutral
No targeton BNGO
Overall win rate
44%
+ Follow
#3
Yi Chen
HC Wainwright & Co. · Rank #350
Buy
$6.00+514.6% to target
Overall win rate
34%
+ Follow
#4
Jason McCarthy
Maxim Group · Rank #567
Buy
$8.00+719.5% to target
Overall win rate
30%
+ Follow
BNGO stock forecast FAQ
What is BNGO's average 12-month price target?+
The 1 active firms with a live target average $6.00 for Bionano Genomics Inc over the next 12 months, ranging from a $6.00 high to a $6.00 low, as of Nov 19, 2026.
Is BNGO stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover BNGO?+
1 active firms have a recognized rating on Bionano Genomics Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BNGO?+
Among analysts who currently cover BNGO, Sung Ji Nam of Scotiabank has the strongest overall Quantellect track record (Rank #186). Their current call is Neutral with a $4.00 target.
What is Bionano Genomics Inc's projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 1 analysts. Full-year EPS is projected at $-2.14, rising to $-0.97 the following year.
How much revenue is Bionano Genomics Inc expected to report next quarter?+
Consensus revenue is $8.4M (range $8.4M – $8.4M). Full-year revenue is projected at $32.5M, growing to $43.3M next year.
Have analysts been upgrading or downgrading BNGO lately?+
As of Nov 19, 2026, 1 of 1 active firms rate BNGO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BNGO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.